FCRL3: A Potential Drug Target and Biomarker for the Treatment of Inflammatory Diseases

Target Name: FCRL3

NCBI ID: G115352

FCRL3: A Potential Drug Target and Biomarker for the Treatment of Inflammatory Diseases

Introduction

FcRL3, also known as human Fc receptor-like protein 3, is a protein that is expressed in various tissues throughout the body. It is a member of the Fc receptor family, which is a type of protein that plays a crucial role in the immune system. FCRL3 has been identified as a potential drug target and biomarker for the treatment of inflammatory diseases, including rheumatoid arthritis, chronic obstructive pulmonary disease (COPD), and inflammatory bowel disease (IBD).

The Importance of FCRL3 as a Drug Target

FCRL3 is a protein that is expressed in the liver, spleen, and other tissues throughout the body. It is a type of transmembrane protein that is characterized by the presence of an extracellular domain, a transmembrane domain, and an intracellular domain. The intracellular domain of FCRL3 is composed of a tail that is involved in protein-protein interactions and is thought to play a role in the regulation of cellular processes.

Studies have shown that FCRL3 is involved in the regulation of various cellular processes, including inflammation, fibrosis, and autophagy. It is also involved in the regulation of cellular signaling pathways, including the TGF-β pathway, which is a critical pathway that is involved in the regulation of cell growth, differentiation, and inflammation.

FCRL3 has been shown to play a role in the regulation of TGF-β signaling in various tissues, including the liver, spleen, and lungs. It is also shown to be involved in the regulation of the production of pro-inflammatory cytokines, such as TNF-伪 and IL-1尾. These cytokines are important drivers of inflammation and contribute to the development and progression of inflammatory diseases.

FCRL3 as a Biomarker

FCRL3 has also been identified as a potential biomarker for the diagnosis and monitoring of inflammatory diseases. The levels of FCRL3 have been shown to be elevated in individuals with inflammatory diseases, such as rheumatoid arthritis, COPD, and IBD.

In rheumatoid arthritis, FCRL3 has been shown to be involved in the regulation of immune cell function and the production of pro-inflammatory cytokines. It is also shown to be involved in the regulation of the development and progression of joint damage in rheumatoid arthritis.

In COPD, FCRL3 has been shown to be involved in the regulation of airway remodeling and the production of pro-inflammatory cytokines. It is also shown to be involved in the regulation of immune cell function and the development of COPD-related lung fibrosis.

In IBD, FCRL3 has been shown to be involved in the regulation of immune cell function and the production of pro-inflammatory cytokines. It is also shown to be involved in the regulation of the development and progression of Crohn's disease-related tissue inflammation.

Conclusion

In conclusion, FCRL3 is a protein that is involved in various cellular processes and has been identified as a potential drug target and biomarker for the treatment of inflammatory diseases. Further research is needed to fully understand the role of FCRL3 in the regulation of inflammation and to develop effective treatments for inflammatory diseases based on this protein.

Protein Name: Fc Receptor Like 3

Functions: Promotes TLR9-induced B-cell proliferation, activation and survival but inhibits antibody production and suppresses plasma cell differentiation. Enhances activation of NF-kappa-B and MAPK signaling pathways in TLR9 stimulated B-cells (PubMed:23857366). Has inhibitory potentional on B-cell receptor (BCR)-mediated signaling, possibly through association with SH2 domain-containing phosphatases. Inhibits cell tyrosine phosphorylation, calcium mobilization and activation-induced cell death induced through BCR signaling (PubMed:19843936). Regulatory T-cells expressing FCRL3 exhibit a memory phenotype, are relatively nonresponsive to antigenic stimulation in presence of IL2 and have reduced capacity to suppress the proliferation of effector T-cells (PubMed:20190142, PubMed:19494275). Acts as a human-specific epitope on the cell surface of oocytes (oolemma) and plays a role during sperm-egg adhesion and fusion (PubMed:36070373). Interacts with the IZUMO1-IZUMO1R/JUNO sperm-egg complex and replaces IZUMO1R/JUNO as IZUMO1 receptor during fertilization, thereby permitting species-specific gamete fusion (PubMed:36070373)

More Common Targets